Body Composition and Aspirin Dose for Colorectal Adenoma Prevention in a Randomized Clinical Trial

Background: Visceral adiposity is a risk factor for colorectal adenomas, and aspirin is an established chemopreventive agent. Evidence from clinical trials suggests the effectiveness of aspirin at preventing cardiovascular disease and cancer may require higher doses for higher body weight. Methods: Body mass index, body surface area, fat-free mass, and fat mass were calculated from baseline height and weight in 1,121 participants of the Aspirin/Folate Polyp Prevention Study, a double-blind, placebo-controlled, 3 × 2 factorial randomized clinical trial of low-dose (81 mg/day) or high-dose (325 mg/day) aspirin and/or 1 mg/day folic acid to prevent metachronous colorectal adenomas. Participants were treated during a surveillance colonoscopy interval of approximately 3 years. Risk ratios (RR) with 95% confidence intervals (CI) for any colorectal neoplasia and high-risk adenoma (HRA, advanced or ≥3 adenomas) were estimated from log-linear regression. Results: We did not find evidence to suggest aspirin dose-response differed by body composition measurements, including weight alone. Among those weighing ≥ 80 kg, treatment effects for low-dose aspirin (RR for colorectal neoplasia, 0.75; 95% CI, 0.60–0.94; RR for HRA, 0.52; 95% CI, 0.31–0.86) and high-dose aspirin (RR for colorectal neoplasia, 0.88; 95% CI, 0.72–1.08; RR for HRA, 0.68; 95% CI, 0.43–1.09) were not meaningfully different than for those weighing 70–79 kg or Conclusions: Measurements of body composition calculated from height and weight did not modify aspirin treatment effects for colorectal adenoma prevention. Impact: Aspirin dosing strategies accounting for body weight suggested in previous trials of colorectal cancer may not apply to adenomas.